Projects per year
Personal profile
Personal profile
Dr. Ho joined the Wisdom Lake Academy of Pharmacy, XJTLU in April 2024 as an Assistant Professor of Practice. He studied chemical biology and molecular biophysics at Academia Sinica and then graduated from Taiwan University. After three years of postdoctoral training in antiviral research, he moved to Beijing, decided to transition his focus towards the CAR-T cell therapy.
Dr. Ho has served as R&D director and Senior R&D Director in Senlang-Taihe biotechnology companies, with one IND approval. At Neukio, as the Principal Scientist, he focused on the development of functional components for editing iPSC derived CAR-NK cells, a pivotal approach of the off-the-shelf immunotherapies before joining XJTLU.
His lab is interested on enhancing the migration and the invasion of immune cells into tumor microenvironment. Moreover, he is also interested in developing nanobodies that can specifically target intracellular neoantigens. Students who are interested in cell therapy are welcome to join us ！
简介
何晋元博士于2024年4月加入西交利物浦大学慧湖药学院，任实践助理教授。本科与研究生阶段就读于台湾阳明交通大学, 主要通过二维电泳与质谱仪鉴定受药物影响的蛋白分子。而后在台湾中央研究院加入国际研究生学程，学习化学生物学和分子生物物理学，主要研究脢类蛋白催化的化学机制，2011年取得台湾大学博士学位。在长庚大学进行了三年的天然物对肠病毒71型与甲型流感的抗病毒研究后，他到了北京并将研究重点转移到CAR-T细胞治疗上。
他曾担任河北森朗以及河北森朗泰禾生物技术公司的研发总监和高级研发总监，所主导的研发项目Senl_B19， 成功获得了IND批准。在加入西交利物浦大学之前，何博士在上海星奕昂任首席科学家，专注于开发用于编辑iPSC衍生CAR-NK细胞的功能组件。实验室对于通过基因或小分子提升免疫细胞功能以及利用病毒、细菌、和各类免疫细胞进行肿瘤联合治疗的研发与应用均有兴趣。欢迎对细胞治疗感兴趣的同学加入！
Research interests
- Viral and non-viral gene editing
- Nanobody screening for tumor-related protein targets
- Cell therapies, including CAR-T and TILs
研究兴趣
- 基于病毒与非病毒载体的基因递送
- 靶向肿瘤相关抗原的纳米抗体筛选
- 细胞治疗
Experience
2024.04- present: Assistant Professor of Practice, XJTLU, Suzhou, China
2022.06-2024.03: Principal Scientist of R&D, Neukio Biotherapeutics, Shanghai, China
2020.07-2022.05: R&D Senior Director, Hebei Senlang-Taihe, Shijiazhuang, China
2018.06-2020.06: R&D Director, Hebei Senlang Biotechnology, Shijiazhuang, China
2016.04-2018.05: Assistant President, Geno-immune Medical Institute, Shenzhen, China
2015.04-2016.03: R&D Manager, Beijing America Yuva, Beijing, China
2012.07-2015.03: Postdoctoral Researcher, Chang-Gung University, Taiwan, China
Teaching
APH423, Pinciples of Toxicology (module leader)
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Related documents
Education/Academic qualification
PhD, TIGP, Taiwan University
Sept 2006 → Jun 2011
Master, Biochemistry, National Yang Ming Chiao Tung University
Sept 2001 → Jun 2003
Bachelor, Life Science, National Yang Ming Chiao Tung University
Sept 1997 → Jun 2001
Keywords
- RM Therapeutics. Pharmacology
- Cell Therapies
- Chimeric Antigen Receptor
- Nanobodies
- Acute Myeloid Leukemia (AML)
- Q Science (General)
Person Types
- Staff
Fingerprint
Dive into the research topics where Jinyuan Ho is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
Jiangsu Province Higher Education Key Laboratory of Cell Therapy Nanoformulation (Construction)
Ruan, G., Lee, M. H., Wu, Q., Lu, T., Xu, P., Loo, S., Sun, Y., Kam, A., Liu, X., Wen, X., Zhang, J., Wang, M., Xu, M., Cheng, K., Zhang, X., Song, J., Guo, B., Wang, Y., Wang, J., Wu, S., Yang, J., Fu, L., Zhang, J., Qiao, Y., Chen, Y., Li, T., Huang, D., Gu, J., Zhan, T., Wan, Y., He, Z., Cheng, Y., Leng, J., Qi, M., Ho, J., Sun, Y., Zhang, N., Soe, H. M. S. H., Ling, C. & Zhou, H.
1/07/24 → 30/06/27
Project: Governmental Research Project
-
Rosmarinic acid interferes with influenza virus A entry and replication by decreasing GSK3β and phosphorylated AKT expression levels
Jheng, J. R., Hsieh, C. F., Chang, Y. H., Ho, J. Y., Tang, W. F., Chen, Z. Y., Liu, C. J., Lin, T. J., Huang, L. Y., Chern, J. H. & Horng, J. T., Aug 2022, In: Journal of Microbiology, Immunology and Infection. 55, 4, p. 598-610 13 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Citations (Scopus) -
First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose
Lin, Q., Ba, T., Ho, J., Chen, D., Cheng, Y., Wang, L., Xu, G., Xu, L., Zhou, Y., Wei, Y., Li, J. & Ling, F., 21 Jun 2021, In: Frontiers in Oncology. 11, 694941.Research output: Contribution to journal › Article › peer-review
Open Access62 Citations (Scopus) -
Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
Ho, J. Y., Wang, L., Liu, Y., Ba, M., Yang, J., Zhang, X., Chen, D., Lu, P. & Li, J., 11 Jun 2021, In: Molecular Therapy Methods and Clinical Development. 21, p. 237-246 10 p.Research output: Contribution to journal › Article › peer-review
Open Access24 Citations (Scopus) -
Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report
Huang, C., Zhang, H. C., Ho, J. Y., Liu, R. X., Wang, L., Kuang, N., Zheng, M. R., Liu, L. H. & Li, J. Q., Oct 2020, In: Oncology Letters. 20, 4, A99.Research output: Contribution to journal › Article › peer-review
Open Access8 Citations (Scopus) -
Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors
Hsieh, C. F., Jheng, J. R., Lin, G. H., Chen, Y. L., Ho, J. Y., Liu, C. J., Hsu, K. Y., Chen, Y. S., Chan, Y. F., Yu, H. M., Hsieh, P. W., Chern, J. H. & Horng, J. T., 1 Jan 2020, In: Emerging Microbes and Infections. 9, 1, p. 1194-1205 12 p.Research output: Contribution to journal › Article › peer-review
Open Access42 Citations (Scopus)